Skip to main content

Advertisement

Table 2 Association between hepatoblastoma risk and NRAS rs2273267 A > T polymorphisms after stratification by age, gender, and clinical stages

From: NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children

Variables rs2273267 (patients/controls) Crude OR (95% CI) P Adjusted ORa (95% CI) P a
AA/AT TT
Age, months
 < 17 102/414 12/40 1.22 (0.62–2.41) 0.571 1.23 (0.62–2.43) 0.556
 ≥ 17 89/467 10/37 1.42 (0.68–2.96) 0.351 1.42 (0.68–2.96) 0.350
Gender
 Female 72/348 12/31 1.87 (0.92–3.82) 0.085 1.84 (0.90–3.77) 0.094
 Male 119/533 10/46 0.97 (0.48–1.99) 0.942 0.97 (0.47–1.97) 0.925
Clinical stages
 I + II 84/881 13/77 1.77 (0.94–3.32) 0.075 1.77 (0.94–3.32) 0.075
 III + IV 48/881 7/77 1.67 (0.73–3.81) 0.225 1.66 (0.73–3.80) 0.229
  1. OR odds ratio, CI confidence interval
  2. aAdjusted for age and gender, with the stratification factor omitted